Jendo Innovations has pioneered a revolutionary medical device designed to advance the early diagnosis of vascular diseases, and this significant investment is poised to propel their innovation into the global healthcare market.
Jendo Innovations’ groundbreaking product, the Jendo device, has garnered widespread attention for its ability to analyze endothelial function, a critical indicator in the early stages of numerous cardiovascular diseases.
By harnessing the power of non-invasive techniques such as Photoplethysmography (PPG) and Digital Thermal Monitoring (DTM), the Jendo device ensures a comfortable and seamless experience for patients while delivering highly accurate results.
The device's cloud-based artificial intelligence system further amplifies its capabilities by efficiently processing and analyzing data.
This makes it an invaluable tool for diagnosing conditions like atherosclerosis, nephropathy, neuropathy, and varicose veins, transforming the landscape of vascular health assessment.
What sets Jendo Innovations apart is its pioneering diagnostics methods for vascular assessment, which has undergone extensive clinical testing and received patents in key markets such as the United States, Japan, and Sri Lanka.
These patents underscore the device's uniqueness and its immense potential to revolutionize vascular health assessment globally.
Lanka Ventures PLC, with major shareholders including Hatton National Bank and DFCC Bank, has primarily focused its investments in the energy and health sectors.
Their decision to invest in Jendo Innovations reflects the firm's commitment to supporting groundbreaking innovations in healthcare technology.
Mr. Damith Pallewatte, Chairman of Lanka Ventures PLC, expressed enthusiasm about the investment, stating,
"We are excited to be a part of Jendo Innovations’ journey.
Their groundbreaking technology has the potential to make a significant impact on global healthcare by enabling early diagnosis of vascular diseases.
We believe in their vision and are confident that this investment will help bring their innovation to market faster."
In response to the investment, Mr. Keerthi Kodithuwakku, the co-founder and CEO of Jendo Innovations, conveyed his gratitude, saying,
"We are thrilled to have Lanka Ventures as our partner.
This investment will accelerate our plans to move from the prototype stage to production.
We also aim to secure regulatory approvals in Sri Lanka, Japan, and the USA, bringing our groundbreaking technology to patients worldwide."
The investment from Lanka Ventures PLC represents a pivotal moment for Jendo Innovations as they prepare to take their pioneering vascular health assessment technology to the global stage.
With the support of this strategic partnership, the Jendo device is poised to become an indispensable tool in the early detection and management of vascular diseases, potentially saving countless lives in the process.
Photo Caption Mr. Damith Pallwatte, Mr. Keerthi Kodithuwakku and Mr. Palitha Gamage at the signing and accepting investment to Jendo Innovations